Age-Dependent Memory Benefits From Pharmacologically Enhanced Naps?

This study is currently recruiting participants.

Verified by University of California, San Diego, October 2008

First Received: October 15, 2008 No Changes Posted

Sponsor:	University of California, San Diego
Information provided by:	University of California, San Diego
ClinicalTrials.gov Identifier:	NCT00773032

Purpose

The purpose of this study is to investigate whether

pharmacologically enhanced naps will show increases in specific sleep stages
whether these sleep stages will produces specific increases on memory tests
whether older adults will benefit more than young adults from increased SWS or Stage 2 on subsequent declarative and motor memory tests.

Condition	Intervention
Older Adults	Drug: Sodium Oxybate Drug: Zolpidem Drug: placebo

Study Type:

Interventional

Resource links provided by NLM:

MedlinePlus related topics: Club Drugs Memory

Drug Information available for: Zolpidem Sodium oxybate

U.S. FDA Resources

Further study details as provided by University of California, San Diego:

Study Start Date:	October 2008
Estimated Primary Completion Date:	June 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Sodium Oxybate: Experimental 2.5g Sodium Oxybate administered during nap	Drug: Sodium Oxybate 2.5g Sodium Oxybate administered during nap
Zolpidem: Experimental 5mg Zolpidem administered during nap	Drug: Zolpidem 5mg Zolpidem administered during nap
Placebo: Placebo Comparator	Drug: placebo Placebo administered during nap

Eligibility

Ages Eligible for Study:	60 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

English-speaking individuals, half men and half women, and between the ages of 60 and 75 years will be recruited. No ethnic group will be specifically excluded from study. All participants will be recruited from general San Diego Community. An education requirement of at least 12 years completed will be imposed, as education may affect performance on the cognitive task.

Exclusion Criteria:

Not having a regular sleep-wake schedule (defined as not meeting criteria listed above and/or a Horne-Ostberg Morningness-Eveningness Questionnaire score not between 31-69)
Having a sleep disorder (reported or detected on the questionnaires)
Any personal or immediate family (i.e., first degree relative) history of diagnosed significant psychopathology
Personal history of head injury with loss of consciousness greater than 15 minutes or seizures
History of substance dependence
Current use of any psychotropic medications
Any cardiac, respiratory or other medical condition which may affect cerebral metabolism
Given the nature of the stimulus and its presentation, anyone with non-correctable vision and audition impairments will also be excluded.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00773032

Contacts

Contact: Jen Kanady, BA

858-642-3192

jkanady@vapop.ucsd.edu

Locations

United States, California
Laboratory for Sleep and Behavioral Neuroscience	Recruiting
La Jolla, California, United States, 92093
Contact: Jen Kanady, BA 858-642-3192 jkanady@vapop.ucsd.edu

Sponsors and Collaborators

University of California, San Diego

More Information

No publications provided

Responsible Party:	( PI: Sara C. Mednick Ph.D. )
Study ID Numbers:	071529_OA
Study First Received:	October 15, 2008
Last Updated:	October 15, 2008
ClinicalTrials.gov Identifier:	NCT00773032 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Zolpidem
Anesthetics, Intravenous
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anesthetics
Central Nervous System Depressants
Pharmacologic Actions

Adjuvants, Anesthesia
Anesthetics, General
Therapeutic Uses
GABA Agonists
Hypnotics and Sedatives
GABA Agents
Central Nervous System Agents
Sodium Oxybate

ClinicalTrials.gov processed this record on February 08, 2010